Therapix shares rise on early data of its repurposed cannabinoid in Tourette syndrome
An Israeli biotech developing cannabinoid-based drugs has found preliminary evidence that its lead product can reduce symptoms in adults suffering from Tourette syndrome.
In a …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
